Galapagos increases share capital through subscription right exercises
Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
Galapagos issued 70,925 new ordinary shares on 4 December 2020, for a total capital increase (including issuance premium) of €2,615,857.50.
Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights.
In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,819,443.97, the total number of securities conferring voting rights amounts to 65,411,767, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (formerly known as warrants) to subscribe to not yet issued securities conferring voting rights is (i) 6,928,337 subscription rights under several outstanding employee subscription right plans, which equals 6,928,337 voting rights that may result from the exercise of those subscription rights, and (ii) one subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 29.9% of the actually issued and outstanding shares after the exercise of the subscription right. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
VP Investor Relations
+1 781 460 1784
Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
Global Head of Communications & Public Affairs
+32 473 824 874
Senior Director Therapy Areas Communications
+44 7717 801900
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Invitation to UPM’s webcast and press conference on Financial Statements for the year 202021.1.2021 09:00:00 CET | Press release
(UPM, Helsinki, 21 January 2021 at 10:00 EET) – UPM will publish its fourth quarter results and Financial Statements for the year 2020 on 28 January 2021 at 09:30-10:00 EET. After publishing the report will be available on company's website at www.upm.com. A webcast and a conference call for analysts and investors in English language begins at 13:15 EET. UPM’s financial results will be presented by the President and CEO Jussi Pesonen and CFO Tapio Korpeinen. All participants can view the webcast online at www.upm.com or through this link, but participants who wish to ask questions must attend the conference call by dialling a number in the list below: Conference call title: Financial Statement Release for the year 2020 International telephone numbers: Argentina Toll: +54 1152526536 Australia Toll: +61 284058549 Austria Toll: +43 19287907 Belgium Toll: +32 24035814 Brazil Toll: +55 1133517266 Bulgaria Toll: +359 29358129 Canada Toll: +1 4162164189 Chile Toll: +56 226188227 China Toll: +
Cargotec’s financial statements review 2020 to be published on Thursday, 4 February 202121.1.2021 08:30:00 CET | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 21 JANUARY 2021 AT 9:30 AM (EET) Cargotec’s financial statements review 2020 to be published on Thursday, 4 February 2021 Cargotec Corporation will publish its financial statements review 2020 on Thursday, 4 February 2021 at approximately 1:30 p.m. EET. The report will be available at www.cargotec.com after publication. A live international telephone conference for analysts, investors and media will be arranged on the publishing day at 3:00 p.m. EET. The event will be held in English. The report will be presented by CEO Mika Vehviläinen and Executive Vice President, CFO Mikko Puolakka. The presentation material will be available at www.cargotec.com by the latest 2:30 p.m. EET. The telephone conference, during which questions may be presented, can be accessed by registering here. The registration opens 15 minutes prior to the event. The event conferencing system will call the participant on the phone number provided and place the participant into the
NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis21.1.2021 08:08:24 CET | Press release
NOT FOR DISTRIBUTION IN THE UNITED KINGDOM NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate as well as severe rheumatoid arthritis (RA) - aiming to avoid irreversible damage as early as possible1More than 400,000 people across the UK live with RA2 and around 70% have moderate or severe disease3 Mechelen, Belgium, 21 January 2021, 08:05 CET – Galapagos NV (Euronext & Nasdaq: GLPG) today welcomed the news that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use of the daily oral pill, JYSELECA®▼ (filgotinib) on the National Health Service (NHS) in England for the treatment of eligible adult patients with moderate to severe active rheumatoid arthritis (RA).1 It is the first time in the UK that an advanced therapy has been recommended in people with moderate RA, offering thousands more the potential to achieve remission earlier - potentially slowing the
Conference call to present Kinnevik’s fourth quarter and full-year results 202021.1.2021 08:00:00 CET | Press release
Kinnevik AB (publ) ("Kinnevik") will publish financial results for the fourth quarter and full-year 2020 on Thursday 4 February 2021 at around 08.00 CET. A conference call will be held on the same day at 10.00 CET to present the results. The presentation will be held in English and also be made available via audiocast on Kinnevik’s website, www.kinnevik.com. Link to the audiocast: https://edge.media-server.com/mmc/p/a97or8rx Those who wish to participate in the conference call are welcome to dial-in on the below numbers. To ensure that you are connected to the conference call, please dial in and register your attendance a few minutes before the conference call begins. Dial-in numbers: UK: +44 3333 000 804 SE: +46 8 566 426 51 US: +1 631 913 1422 Confirmation code: 69100644# For further information, visit www.kinnevik.com or contact: Torun Litzén, Director Investor Relations Phone +46 (0)70 762 00 50 Email email@example.com Kinnevik is an industry focused investment company with an ent
Telefonkonferens och presentation av Kinneviks resultat för fjärde kvartalet och helåret 202021.1.2021 08:00:00 CET | Pressemelding
Kinnevik AB (publ) ("Kinnevik") kommer att offentliggöra resultatet för det fjärde kvartalet och helåret 2020 torsdagen den 4 februari 2021 cirka kl. 08.00 CET. En telefonkonferens kommer att hållas samma dag kl. 10.00 CET för att presentera resultatet. Presentationen kommer att hållas på engelska och även finnas tillgänglig som audiocast på Kinneviks webbplats, www.kinnevik.com. Länk till audiocast: https://edge.media-server.com/mmc/p/a97or8rx De som vill delta i telefonkonferensen i samband med presentationen är välkomna att ringa in på nedanstående nummer. För att vara säker på att uppkopplingen till konferenssamtalet fungerar, ring in några minuter innan konferensen börjar för att registrera er. Telefonnummer: UK: +44 3333 000 804 SE: +46 8 566 426 51 US: +1 631 913 1422 Kod: 69100644# För ytterligare information, besök www.kinnevik.com eller kontakta: Torun Litzén, Informations- och IR-chef Telefon +46 (0)70 762 00 50 Email firstname.lastname@example.org Kinnevik är ett sektorfokuserat invest
Huhtamaki invests in new state-of-the-art manufacturing unit in Malaysia21.1.2021 08:00:00 CET | Press release
HUHTAMÄKI OYJ PRESS RELEASE 21.1.2021 AT 09:00 Huhtamaki invests in new state-of-the-art manufacturing unit in Malaysia Huhtamaki, a key global provider of sustainable packaging solutions for consumers around the world, is investing in a new manufacturing site in Malaysia. In order to better serve its customers and respond to future growth of the sector in Southeast Asia, the company is transferring its Malaysian manufacturing base from Penang to Port Klang, Selangor State, the capital region of Malaysia. The new site is expected to be fully operational by the end of the second quarter of 2021. “By investing in a world-class facility in Malaysia we are creating a platform for future growth in Southeast Asia. The new site is strategically located, it is close to our key customers and has easy access to neighboring countries. We will also use the relocation as an opportunity to modernize our equipment and increase automation to improve efficiency. Our initial focus will be on manufacturi
Agfa-Gevaert: Agfa intends to reorganize its Offset Solutions activities – Regulated information21.1.2021 07:45:00 CET | Press release
Mortsel, Belgium – January 21, 2021 – 7:45 a.m. CET This press release contains inside information. On January 20, 2021, the Board of Directors expressed the intention to organize the Offset Solutions activities into a stand-alone legal entity structure and organization within the Agfa-Gevaert Group. This intended reorganization is part of the strategic transformation program for the Agfa-Gevaert Group, To improve profitability and to address the significant decline in market demand, Agfa is reviewing its offset business model, simplifying its organization and streamlining its product offering. About Agfa The Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions, HealthCare IT, Digital Print & Chemicals and Offset Solutions. They develop, manufacture and market analogue and digital systems for the healthcare sector, for specific industrial applications and for the printing in